
About Chroma Medicine
Chroma Medicine is a Healthcare company based in Cambridge (United States) founded in 2020. Epigenetic editing platform is developed for genomic medicines. Chroma Medicine has raised $135 million across 3 funding rounds from investors including ARE, T. Rowe Price and Janus Henderson Investors. The company has 122 employees. Chroma Medicine has completed 1 acquisition, including Epsilen Bio. Its chief executive, as recorded, is Catherine Stehman Breen. Chroma Medicine offers products and services including Epigenetic Editors, DLVR Particles, and CRMA-1001. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include FOXO Technologies, Reaction Biology and Epinoma; 1 of its 3 listed competitors has raised funding.
Company details
Chroma Medicine was founded in 2020 and is based in Cambridge, United States. An epigenetic editing platform is developed by the company within the biotechnology sector, focusing on genomic medicines. Gene expression is modulated through precise targeting of the epigenome, without changes to the underlying DNA sequence. This approach is applied to address diseases driven by genetic factors, supporting operations in research and therapeutic development.
- Headquarters Cambridge, United States
- Employees 122
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website chromamedicine.com
- Social LinkedIn X
- Total Equity Funding$135M (USD)
in 3 rounds
- Latest Funding Round$135M (USD), Series B
Feb 2023
- InvestorsARE
& 17 more
- Employee Count122
- Investments & Acquisitions
Products & Services of Chroma Medicine
Chroma Medicine offers a comprehensive portfolio of products and services, including Epigenetic Editors, DLVR Particles, and CRMA-1001.
Enables one-time cures by regulating genes without DNA changes.
Facilitates efficient, cell-specific delivery of macromolecules for editing.
Targets chronic hepatitis B for deep, durable gene silencing.
Funding Insights of Chroma Medicine
Chroma Medicine has successfully raised a total of $135M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135M
- Total Rounds 3
- Last Round Series B β $135M
- Investors Count 18
All 3 funding rounds of Chroma Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $135M | Series B | β | Google Ventures | |
| Nov 2021 | Series A | β | Cormorant-asset | ||
| Jun 2020 | Seed | β | Newpath Partners, Atlas Venture |
18 investors in total: 18 institutional.
Investors in Chroma Medicine
Chroma Medicine has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, T. Rowe Price and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Private equity and debt investments are managed across multiple sectors. | sixthstreet.com | San Francisco, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital firm | omegafunds.com | Boston, United States | ||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Investment management services are offered by Newpath Partners. | newpath.partners | Boston, United States |
Investor details for Chroma Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chroma Medicine
26 people are tracked at Chroma Medicine (6 in leadership, 10 in board & advisors, 10 in team); the tracked headcount is 122.
| Name | Role | Group |
|---|---|---|
Catherine Stehman Breen | CEO | Leadership |
Sivan Harel | Director, Translational Biomarkers & Bioanalytics | Leadership |
Cecilia Fernandez | VP, Strategic Planning & Operations | Leadership |
Tobias Brambrink | VP, Intellectual Property | Leadership |
Sahar Abubucker | VP, Data Sciences | Leadership |
Adam Connelly | Director Of Quality Control | Leadership |
Howard Chang | Advisor | Board & advisors |
Luke Gilbert | Founder | Board & advisors |
J. Keith Joung | Founder | Board & advisors |
Jonathan Weissman | Founder | Board & advisors |
Ahmad Khalil | Advisor | Board & advisors |
David Liu | Founder | Board & advisors |
Angelo Lombardo | Founder | Board & advisors |
Luigi Naldini | Founder | Board & advisors |
Bradley Bernstein | Advisor | Board & advisors |
Paula Cannon | Advisor | Board & advisors |
Melissa Pannone | Associate Scientist I | Team |
Kyle Runckel | Scientist II | Team |
Hasit Lunagaria | SVP, People & Culture | Team |
Lenka Kundrat Hoffman | Principal Scientist | Team |
6 more people are available in the full profile.
Complete people profiles for Chroma Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chroma Medicine
Chroma Medicine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epsilen Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Epigenetic gene silencing technologies are developed for disease treatments. | epsilenbio.com | Milano, Italy | 2019 | Nov 2021 | β’β’β’β’ |
Complete acquisition details for Chroma Medicine
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Chroma Medicine
4 dated milestones of Chroma Medicine across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Chroma Medicine is founded.
- Funding First funding round.
- Acquisition Acquires Epsilen Bio.
- Funding Latest funding round, Series B, of $135.0M.
Competitors of Chroma Medicine
Chroma Medicine has 3 listed competitors in our database, 1 of them funded. They include FOXO Technologies, Reaction Biology and Epinoma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| foxotechnologies.com | 2020 | Minneapolis, United States | Epigenetic biomarkers are discovered and developed via AI platforms. | |||
| reactionbiology.com | 2001 | United States | 77 | In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling | ||
| epinoma.com | 2020 | San Carlos, United States | $125,000 | 4 | Limited information available |
Detailed competitors of Chroma Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Chroma Medicine
Websites that share an audience with Chroma Medicine (chromamedicine.com).
Websites whose visitors overlap most with Chroma Medicine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cuebiopharma.com | 100% | 4.9K | #7,063,180 | View details | |
| sherlock.bio | 97% | 2.8K | #4,929,420 | View details | |
| lyndra.com | 96% | #9,629,878 | View details | ||
| ornatx.com | 95% | 4.4K | #3,250,511 | View details | |
| dynotx.com | 93% | 14.4K | #2,089,404 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Chroma Medicine
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Chroma Medicine (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chroma Medicine
Complete news archive for Chroma Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chroma Medicine
Chroma Medicine was founded in 2020.
Chroma Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Catherine Stehman Breen is the CEO of Chroma Medicine, as recorded in our data.
Chroma Medicine is a funded company, having raised a total of $135M across 3 funding rounds to date.
Chroma Medicine has 122 employees.
Chroma Medicine was founded in 2020 and is based in Cambridge, United States. An epigenetic editing platform is developed by the company within the biotechnology sector, focusing on genomic medicines. Gene expression is modulated through precise targeting of the epigenome, without changes to the underlying DNA sequence. This approach is applied to address diseases driven by genetic factors, supporting operations in research and therapeutic development.
Chroma Medicine's top competitors include FOXO Technologies, Reaction Biology and Epinoma.
Chroma Medicine offers Epigenetic Editors, DLVR Particles, and CRMA-1001.
Chroma Medicine has made 1 acquisition, including Epsilen Bio.
Chroma Medicine has 18 investors. Key investors include ARE, T. Rowe Price, Janus Henderson Investors, Arch Venture Partners, and Atlas Venture.
